Semaglutide(Rybelsus)

Semaglutide tablets were approved by the U.S. FDA in January 2020 and are a prescription medication targeting the glucagon-like peptide-1 (GLP-1) receptor.

Target of Action

Glucagon-like peptide-1 (GLP-1) receptor

Dosage and Administration

Route and frequency of administration of Semaglutide: oral, once daily.

The dose of Semaglutide should be adjusted according to the patient's actual condition. Please contact your doctor and follow their instructions.

Recommended reading: Dosage and administration of Semaglutide

Side Effects

Common side effects: nausea, stomach pain, diarrhea, etc.

Serious side effects: pancreatitis, vision changes, hypoglycemia, etc.

Reference article: Side effects of Semaglutide

Use in Special Populations

Pregnancy: It is currently unknown whether Semaglutide can harm an unborn baby. Semaglutide should be stopped two months before planning a pregnancy.

Breastfeeding: Breastfeeding is not recommended during treatment with Semaglutide.

Daily Precautions

1. Inform patients that Semaglutide caused thyroid C-cell tumors in rats, and the relevance of this finding for humans is unclear. Advise patients treated with Semaglutide to report promptly if they develop symptoms suggestive of thyroid cancer, such as a neck mass, hoarseness, dysphagia, or dyspnea.

2. Inform patients that pancreatitis may occur during treatment with Semaglutide and describe the signs and symptoms of pancreatitis, including persistent severe abdominal pain sometimes radiating to the back, with or without vomiting. Emphasize that if such symptoms occur, patients must stop Semaglutide immediately and notify their clinician promptly.

3. Inform patients not to share the Semaglutide injection pen with another person, even if the needle is changed. Sharing the injection pen may pose a risk of transmitting or acquiring infectious diseases.

FDA，2025.10